355 citations
,
January 2017 in “Journal of the American Academy of Dermatology” This review reports no new results and highlights existing research suggesting JAK inhibitors may be effective in treating inflammatory skin conditions like alopecia areata, atopic dermatitis, psoriasis, and vitiligo.
277 citations
,
December 2019 in “Frontiers in Immunology” This review discusses the immunological basis and development of Janus kinase inhibitors for treating skin diseases and reports no new clinical findings.
223 citations
,
September 2018 in “Rheumatology” This review examines clinical data on the efficacy and safety of JAK inhibitors used for immune-mediated conditions beyond rheumatoid arthritis, highlighting their potential therapeutic roles in various inflammatory diseases.
42 citations
,
April 2021 in “JCI insight” In this study, selective inhibition of JAK3 signaling effectively prevented and reversed alopecia areata in a mouse model, while JAK2 inhibitors did not restore hair growth.
40 citations
,
June 2021 in “Clinical, cosmetic and investigational dermatology” This review explores the efficacy and outcomes of using JAK inhibitors for treating alopecia areata, noting advancements in understanding the disease's pathomechanisms and suggesting that JAK inhibitors may offer targeted therapeutic benefits by blocking specific inflammatory pathways involved in this chronic condition.